Barclays’s Kyverna Therapeutics KYTX Stock Holding History

Barclays’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$926K	Buy	136,134 +18,290	+16%	+$144K	﹤0.01%	3102
2026 Q2	$1.05M	Sell	117,844 -18,531	-14%	-$165K	﹤0.01%	2764
2026 Q1	$1.18M	Sell	136,375 -28,293	-17%	-$236K	﹤0.01%	2657
2025 Q4	$1.55M	Buy	164,668 +88,477	+116%	+$657K	﹤0.01%	3111
2025 Q3	$457K	Buy	76,191 +25,797	+51%	+$103K	﹤0.01%	3864
2025 Q2	$155K	Sell	50,394 -30,996	-38%	-$76.7K	﹤0.01%	4402
2025 Q1	$157K	Sell	81,390 -8,196	-9%	-$24.2K	﹤0.01%	4174
2024 Q4	$335K	Buy	89,586 +19,419	+28%	+$93K	﹤0.01%	4060
2024 Q3	$343K	Buy	70,167 +12,418	+22%	+$95.7K	﹤0.01%	4002
2024 Q2	$433K	Buy	57,749 +14,655	+34%	+$224K	﹤0.01%	3125
2024 Q1	$1.07M	Buy	+43,094	New	+$1.2M	﹤0.01%	3068

Other funds holding KYTX

Gilead Sciences Foster City, California $1.46B AUM 71.23% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

ACPLP

ACT Capital Partners, L.P. Wayne, Pennsylvania $154M AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Barclays's KYTX Position: Q3 2026 in Review

Barclays increased its Kyverna Therapeutics (KYTX) stake by 16% in Q3 2026, buying an estimated $144K and bringing the position to 136,134 shares worth $926K. The position accounts for ﹤0.01% of the portfolio, ranked #3102.

Barclays first reported a position in KYTX in Q1 2024 and has held it in 11 quarters since. The position peaked at $1.55M in Q4 2025. 41 funds tracked by Wall St. Rank hold KYTX as of Q3 2026.

Barclays held 136,134 shares of Kyverna Therapeutics worth $926K as of Q3 2026.
Barclays bought 18,290 Kyverna Therapeutics shares in Q3 2026, an estimated $144K.
Kyverna Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3102 holding.
Barclays first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 11 quarters since.
Barclays's Kyverna Therapeutics position peaked at $1.55M in Q4 2025.
41 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.